These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
174 related items for PubMed ID: 2537141
1. Novobiocin- and phorbol-12-myristate-13-acetate-induced differentiation of human leukemia cells associated with a reduction in topoisomerase II activity. Constantinou A, Henning-Chubb C, Huberman E. Cancer Res; 1989 Mar 01; 49(5):1110-7. PubMed ID: 2537141 [Abstract] [Full Text] [Related]
2. Effect of phorbol ester treatment on drug-induced, topoisomerase II-mediated DNA cleavage in human leukemia cells. Zwelling LA, Chan D, Hinds M, Mayes J, Silberman LE, Blick M. Cancer Res; 1988 Dec 01; 48(23):6625-33. PubMed ID: 2846155 [Abstract] [Full Text] [Related]
6. Specific protein phosphorylation in human promyelocytic HL-60 leukemia cells susceptible or resistant to induction of cell differentiation by phorbol-12-myristate-13-acetate. Anderson NL, Gemmell MA, Coussens PM, Murao S, Huberman E. Cancer Res; 1985 Oct 01; 45(10):4955-62. PubMed ID: 3861240 [Abstract] [Full Text] [Related]
7. Retinoic acid and phorbol ester induced hyperphosphorylation of topoisomerase II-alpha is an early event in HL-60 human leukaemia cell differentiation: effect on topoisomerase activity and etoposide sensitivity. Chresta CM, Hall BF, Francis GE. Leukemia; 1995 Aug 01; 9(8):1373-81. PubMed ID: 7643627 [Abstract] [Full Text] [Related]
8. Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line. Harker WG, Slade DL, Parr RL, Feldhoff PW, Sullivan DM, Holguin MH. Cancer Res; 1995 Apr 15; 55(8):1707-16. PubMed ID: 7712479 [Abstract] [Full Text] [Related]
12. Protein kinase C activities with different characteristics, including substrate specificity, from two human HL-60 leukemia cell variants. Homma Y, Gemmell MA, Huberman E. Cancer Res; 1988 May 15; 48(10):2744-8. PubMed ID: 3162823 [Abstract] [Full Text] [Related]
13. Resistance to etoposide in human leukemia HL-60 cells: reduction in drug-induced DNA cleavage associated with hypophosphorylation of topoisomerase II phosphopeptides. Ganapathi R, Constantinou A, Kamath N, Dubyak G, Grabowski D, Krivacic K. Mol Pharmacol; 1996 Aug 15; 50(2):243-8. PubMed ID: 8700130 [Abstract] [Full Text] [Related]
14. Induction of the differentiation of WEHI-3B D+ monomyelocytic leukemia cells by inhibitors of topoisomerase II. Rappa G, Lorico A, Sartorelli AC. Cancer Res; 1990 Oct 15; 50(20):6723-30. PubMed ID: 2170008 [Abstract] [Full Text] [Related]
17. Molecular analysis of a potentially phorbol-regulatable region of the human topoisomerase II alpha gene promoter. Loflin PT, Hochhauser D, Hickson ID, Morales F, Zwelling LA. Biochem Biophys Res Commun; 1994 Apr 15; 200(1):489-96. PubMed ID: 8166723 [Abstract] [Full Text] [Related]
18. Altered phosphorylation, biosynthesis and degradation of the 170 kDa isoform of topoisomerase II in amsacrine-resistant human leukemia cells. Ganapathi R, Zwelling L, Constantinou A, Ford J, Grabowski D. Biochem Biophys Res Commun; 1993 May 14; 192(3):1274-80. PubMed ID: 8389546 [Abstract] [Full Text] [Related]
19. Phorbol ester induces apoptosis in HL-60 promyelocytic leukemia cells but not in HL-60 PET mutant. Macfarlane DE, O'Donnell PS. Leukemia; 1993 Nov 14; 7(11):1846-51. PubMed ID: 8231252 [Abstract] [Full Text] [Related]